MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance-Reference-Cited by-同舟云学术

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance

Published:2016-08-16 Issue:10 Volume:87 Page:1138-1145
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Wijburg Martijn T,Witte Birgit I,Vennegoor Anke,Roosendaal Stefan D,Sanchez Esther,Liu Yaou,Martins Jarnalo Carine O,Uitdehaag Bernard MJ,Barkhof Frederik,Killestein Joep,Wattjes Mike P

Funder

Stichting MS Research

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Surgery

Reference39 articles.

1. Risks and benefits of multiple sclerosis therapies: need for continual assessment?;Kieseier;Curr Opin Neurol,2011

2. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview;Rommer;Clin Exp Immunol,2014

3. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy;Warnke;Ann Neurol,2014

4. Natalizumab: bench to bedside and beyond;Rudick;JAMA Neurol,2013

5. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring;Kappos;Lancet Neurol,2011

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Routine MR Imaging Protocol and Standardization in Central Nervous System Demyelinating Diseases;Neuroimaging Clinics of North America;2024-08

2. Treatment Monitoring in Multiple Sclerosis — Efficacy and Safety;Neuroimaging Clinics of North America;2024-08

3. Progressive Multifocal Leukoencephalopathy in a Patient With Cirrhosis and Hepatocellular Carcinoma;The Neurohospitalist;2024-06-03

4. Neuroimaging in multiple sclerosis and related disorders;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024

5. Progressive Multifocal Leukoencephalopathy;Neurology;2023-10-17